Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Author Mistry, Pramod K. Google Scholar
Balwani, Manisha Google Scholar
Baris, Hagit N. Google Scholar
Ben Turkia, Hadhami Google Scholar
Burrow, T. Andrew Google Scholar
Charrow, Joel Google Scholar
Cox, Gerald F. Google Scholar
Danda, Sumita Google Scholar
Dragosky, Marta Google Scholar
Drelichman, Guillermo Google Scholar
El-Beshlawy, Amal Google Scholar
Fraga, Cristina Google Scholar
Freisens, Selena Google Scholar
Gaemers, Sebastiaan Google Scholar
Hadjiev, Evgueniy Google Scholar
Kishnani, Priya S. Google Scholar
Lukina, Elena Google Scholar
Maison-Blanche, Pierre Google Scholar
Martins, Ana Maria Autor UNIFESP Google Scholar
Pastores, Gregory Google Scholar
Petakov, Milan Google Scholar
Judith Peterschmitt, M. Google Scholar
Rosenbaum, Hanna Google Scholar
Rosenbloom, Barry Google Scholar
Underhill, Lisa H. Google Scholar
Cox, Timothy M. Google Scholar
Language English
Date 2018
Published in Blood Cells Molecules And Diseases. San Diego, v. 71, p. 71-74, 2018.
ISSN 1079-9796 (Sherpa/Romeo, impact factor)
Publisher Academic Press Inc Elsevier Science
Extent 71-74
Origin http://dx.doi.org/10.1016/j.bcmd.2018.04.001
Access rights Open access Open Access
Type Letter
Web of Science ID WOS:000432496500013
URI http://repositorio.unifesp.br/handle/11600/45968

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account